Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2018/02/012115
CTRI/2018/02/012115RecruitingNot Applicable

Virechana karma along with Vaitarana Basti followed by Maha Bhallataka Avaleha in the managementof Amavata w.s.r. to Rheumatoid Arthritis - A Comparative Rondomized Controlled Study

Institute for Post Graduate Teaching and Research in Ayurved jamnagar1 site in 1 country40 target enrollmentStarted: February 16, 2018Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
40
Locations
1
Primary Endpoint
1. Change in the DAS28-CRP or DAS-ESR
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

TO ASSESS THE CLINICAL EFFICACY OF SHODHANA KARMA (VIRECHANA KARMA FOLLOWED BY VAITARANA BASTI ) AND MAHA BHALLATAKA AVALEHA IN THE MANAGEMENT OF AMAVATA (RHEUMATOID ARTHRITIS), AND ALSO SAFETY OF AYURVEDA TREATMENT IN THE DIGESTIVE SYSTEM .

HYPOTHESIS ARE

SHODHANA THERAPY IS FACILITATE THE EFFICACY OF SHAMANA THERAPY.

Study Design

Study Type
Interventional
Allocation
Computer generated randomization
Masking
Open Label

Eligibility Criteria

Ages
18.00 Year(s) to 60.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • •Patient who is born and grown up in India
  • •Willing and able to perticipate in the study
  • •Patient having sign and symptoms of Amavata
  • •Patinet who has Rheumatoid Arthritis with fullfill Diagnostic criteria(RF, ANTI CCP, ESR)
  • •Chronicity less than 7 years PATIENTS FIT FOR PANCHAKARMA THERAPY
  • •PATIENTS WHO IS POSITIVE IN ACR/EULAR TEST AND ACR SCORE.

Exclusion Criteria

  • •(1)Patients having severe systemic illness such as: Cardiac failure.
  • •(2)Patients below 18 year and above 60 years (3)Pregnant/lactating women (4)Chronicity more than 7 and more years (5)Active or chronic hepatitis (6)Patient born and grownup in other than India (7)Patient not fit for Panchakarma therapy.

Outcomes

Primary Outcomes

1. Change in the DAS28-CRP or DAS-ESR

Time Frame: 84 weeks

2.Change in the SF-36

Time Frame: 84 weeks

3.Change in the Ayurvedic Parameters for Amavata and Agni.

Time Frame: 84 weeks

Secondary Outcomes

  • to evaluate the efficacy of differenet varieties of ayurvedic treatment in the management of amavata(rheumatoid arthritis)(RA Factore)

Investigators

Sponsor
Institute for Post Graduate Teaching and Research in Ayurved jamnagar
Sponsor Class
Research institution and hospital

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 2
Role of virechana (purgation) in diabetes
CTRI/2018/02/011668Rishikul campus Uttarakhanad Ayurveda university haridwar40
Recruiting
Phase 2
Effect of Virechana Karma on Metabolic Syndrome
CTRI/2017/06/008934Rishikul Campus Uttarakhand Ayurved University30
Completed
Phase 3
Comparision between Vamana Karma and Virechana Karma in Shwitra or Vitiligo.
CTRI/2020/03/023750IPGT and RA22
Completed
Phase 3
Reduction of Khalitya(Hairfall) by Virechana Karma(Purgation) using Abhayadi Modak
CTRI/2015/01/005451Dr Swati Kanungo30
Completed
Not Applicable
Effect of Virechana Karma and Nishadi Vati in the management of Eczema.
CTRI/2016/05/006901Govt Akandanand Ayurved College30